RenovoRx, Inc. (RNXT)
RNXT moved a median of -0.65% 30 minutes after news, and -0.97% by the close. How RNXT actually reacts to news — the realized, point-in-time move the market made, measured across 247 labeled events over the last three years with zero look-ahead.
RNXT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 216 |
| 30-min | -0.65% | 39% | 236 |
| 60-min | -0.36% | 45% | 242 |
| to close | -0.97% | 42% | 245 |
| Middle 50% of RNXT reactions | -2.15% to +1.97% |
|---|---|
| Median reaction (30-min) | -0.65% |
| Measured reactions | 247 |
Half of all RenovoRx, Inc. news events land between -2.15% and +1.97% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RNXT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.12% | 50% | -0.71% |
| Coverage initiations | 10 | 0.00% | 30% | +3.03% |
| Rating reiterations | 18 | +1.41% | 56% | -0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how RNXT ranks against every other measured name →
That’s how RNXT usually reacts — get an email when it moves on news →Email me when RNXT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RNXT's baseline. Nothing else.
Recent RNXT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form RW RenovoRx, Inc. | SEC filing · Form RW | SEC EDGAR | -0.83% | -5.79% | |
| RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial | Press release | GlobeNewswire | -3.33% | +1.48% | |
| RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer | Press release | GlobeNewswire | -0.32% | -1.27% | |
| RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th | Press release | GlobeNewswire | +6.55% | +17.76% | |
| RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer | Press release | GlobeNewswire | +3.46% | +9.23% | |
| RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | -0.39% | +1.54% | |
| Form 8-K RenovoRx, Inc. For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | +1.54% | |
| RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment | Press release | GlobeNewswire | -0.39% | +2.33% | |
| Form 10-Q RenovoRx, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.76% | +10.24% | |
| Form 8-K/A RenovoRx, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +10.24% | |
| Form 8-K RenovoRx, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +5.36% | +12.50% | |
| RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth | Press release | GlobeNewswire | +5.36% | +12.50% | |
| RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer | Press release | GlobeNewswire | -1.39% | -0.86% | |
| RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors | Press release | GlobeNewswire | +1.51% | +7.48% | |
| Form 8-K RenovoRx, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -1.89% | +0.00% | |
| RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th | Press release | GlobeNewswire | +0.92% | +6.00% | |
| RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET | Press release | GlobeNewswire | +0.00% | -1.31% | |
| Form 8-K RenovoRx, Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.15% | |
| Form 8-K RenovoRx, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -5.89% | -3.52% | |
| Form S-8 RenovoRx, Inc. | SEC filing · Form S-8 | SEC EDGAR | -5.89% | -3.52% | |
| RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer | Press release | GlobeNewswire | +0.00% | -1.09% | |
| RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd | Press release | GlobeNewswire | -4.26% | +7.19% | |
| RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer | Press release | GlobeNewswire | -5.16% | +7.80% | |
| RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | -2.43% | +3.90% | |
| RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th | Press release | GlobeNewswire | +0.13% | +4.66% | |
| Form 10-K/A RenovoRx, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.21% | -5.64% | |
| Form 10-Q RenovoRx, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.74% | -4.65% | |
| Form 8-K RenovoRx, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | -4.65% | |
| RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter | Press release | GlobeNewswire | -1.74% | -4.65% | |
| Form DEF 14A RenovoRx, Inc. For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +2.71% | |
| RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET | Press release | GlobeNewswire | +0.61% | +1.35% | |
| Form EFFECT RenovoRx, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.02% | -3.45% | |
| RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +2.13% | -4.25% | |
| Form S-3 RenovoRx, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.09% | +1.01% | |
| Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting | Press release | GlobeNewswire | -3.85% | -0.96% | |
| Form D RenovoRx, Inc. | SEC filing · Form D | SEC EDGAR | — | +5.04% | |
| RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum | Press release | GlobeNewswire | -3.15% | -1.16% | |
| RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 | Press release | GlobeNewswire | +0.39% | -0.88% | |
| Form S-8 RenovoRx, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.01% | -2.02% | |
| Form 10-K RenovoRx, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.21% | -7.34% | |
| Form 8-K RenovoRx, Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -3.21% | -7.34% | |
| RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -3.21% | -7.34% | |
| Form 8-K RenovoRx, Inc. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -0.87% | -1.74% | |
| RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment | Press release | GlobeNewswire | +1.36% | +5.46% | |
| Form 8-K RenovoRx, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | +12.12% | |
| RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement | Press release | GlobeNewswire | +1.01% | +12.12% | |
| RenovoRx Announces $10 Million at Market Private Placement | Press release | GlobeNewswire | +0.99% | +1.98% | |
| RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum | Press release | GlobeNewswire | -5.91% | -4.02% | |
| RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting | Press release | GlobeNewswire | -2.35% | -5.09% | |
| RenovoRx Establishes RenovoCath® Medical Advisory Board | Press release | GlobeNewswire | +1.38% | +2.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RNXT section they belong to.
Where else RNXT is measured.
RNXT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is RenovoRx, Inc.'s median reaction calculated?
Every labeled RNXT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 247 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of RNXT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RNXT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.